219 related articles for article (PubMed ID: 38630132)
41. Updates on thrombotic events associated with multiple myeloma.
Fotiou D; Gavriatopoulou M; Ntanasis-Stathopoulos I; Migkou M; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2019 May; 12(5):355-365. PubMed ID: 30957573
[TBL] [Abstract][Full Text] [Related]
42. Perioperative venous thromboembolism prophylaxis in prostate cancer surgery.
Klaassen Z; Wallis CJD; Lavallée LT; Violette PD
World J Urol; 2020 Mar; 38(3):593-600. PubMed ID: 30840115
[TBL] [Abstract][Full Text] [Related]
43. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
44. Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient.
Lewis TC; Cortes J; Altshuler D; Papadopoulos J
J Intensive Care Med; 2019; 34(11-12):877-888. PubMed ID: 30165770
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the Quality and Safety of Venous Thromboembolism Prophylaxis Among Gastroenterology Inpatients at a Tertiary Hospital in Australia.
van Oosterom N; De Guzman KR; Winckel K; Johnson A; Falconer N
Hosp Pharm; 2023 Dec; 58(6):595-604. PubMed ID: 38560547
[No Abstract] [Full Text] [Related]
46. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Chalayer E; Talbot A; Frenzel L; Karlin L; Collet P; Guyotat D; Attal M; Leleu X; Tardy B
J Thromb Haemost; 2022 Aug; 20(8):1859-1867. PubMed ID: 35557490
[TBL] [Abstract][Full Text] [Related]
47. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents.
Calafiore V; Giamporcaro S; Conticello C; Romano A; Parisi M; Giuffrida G; Tibullo D; Di Raimondo F; Signorelli SS
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899553
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma.
Sánchez Prieto I; Gutiérrez Jomarrón I; Martínez Vázquez C; Rodríguez Barquero P; Gili Herreros P; García-Suárez J
J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38676874
[TBL] [Abstract][Full Text] [Related]
49. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Carrier M; Le Gal G; Tay J; Wu C; Lee AY
J Thromb Haemost; 2011 Apr; 9(4):653-63. PubMed ID: 21255254
[TBL] [Abstract][Full Text] [Related]
50. Venous thromboembolism risk assessment and prophylaxis in hospitalised medical patients in the Cape Town metropole, South Africa.
Wehmeyer A; Coetzee R; McCartney J
S Afr Med J; 2022 Feb; 112(2):13506. PubMed ID: 35139994
[TBL] [Abstract][Full Text] [Related]
51. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Dima D; Li A; Granat LM; Dhillon P; Chamseddine F; Yalamanchali A; Mirzai S; Wei W; Samaras CJ; Valent J; Anwer F; Khouri J
Br J Haematol; 2023 Apr; 201(2):280-284. PubMed ID: 36604838
[TBL] [Abstract][Full Text] [Related]
52. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.
Wu O; Robertson L; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Langhorne P; Brenkel I; Regan L; Greer I
Health Technol Assess; 2006 Apr; 10(11):1-110. PubMed ID: 16595080
[TBL] [Abstract][Full Text] [Related]
53. Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools.
Fotiou D; Gavriatopoulou M; Terpos E
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940972
[TBL] [Abstract][Full Text] [Related]
54. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
55. [Pharmacological Thromboprophylaxis in Acutely Ill Hospitalized Medical Patients].
Kantor B; Poénou G; Plaisance L; Toledano E; Mekhloufi Y; Helfer H; Djennaoui S; Mahé I
Rev Med Interne; 2022 Jan; 43(1):9-17. PubMed ID: 33895004
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.
Sanfilippo KM; Carson KR; Wang TF; Luo S; Edwin N; Kuderer N; Keller JM; Gage BF
Res Pract Thromb Haemost; 2022 Jan; 6(1):e12634. PubMed ID: 35028491
[TBL] [Abstract][Full Text] [Related]
57. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
58. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Piedra K; Peterson T; Tan C; Orozco J; Hultcrantz M; Hassoun H; Mailankody S; Lesokhin A; Shah U; Lu S; Patel D; Derkach A; Wilkins CR; Korde N
Br J Haematol; 2022 Jan; 196(1):105-109. PubMed ID: 34396516
[TBL] [Abstract][Full Text] [Related]
59. Venous thromboembolism: identifying patients at risk and establishing prophylaxis.
Shirvanian S; Tapson VF
Curr Med Res Opin; 2015 Dec; 31(12):2297-311. PubMed ID: 26414590
[TBL] [Abstract][Full Text] [Related]
60. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
